TO TREAT DUCHENNE MUSCULAR DYSTROPHY WITH AGAMREE (VAMOROLONE)

Q: How many days will it take for my paper to be published?

The review time for papers is not fixed. However, if the paper is accepted and the author completes the processing charges formalities, the paper will be published within a few working days.

Q: I would like to receive a hard copy of the journal materials. Are there any additional charges?

You can log in to the author portal and pay 500 INR to receive the hard copy materials.

bhosale ayush; Kawade Madhuri; Rathod Krushna; Hatwar Nandini

TO TREAT DUCHENNE MUSCULAR DYSTROPHY WITH AGAMREE (VAMOROLONE)

Authors: bhosale ayush, Kawade Madhuri, Rathod Krushna, Hatwar Nandini

Unique Paper ID: 180932
Volume: 12
Issue: 1
PageNo: 3442-3458

Keywords: DMD Agamree corticosteroid Vamorolone address hypoventilation.

Abstract:
The dystrophin protein, which is necessary for safeguarding muscle cells during contraction, is not produced in Duchenne due to mutations in the DMD gene. Patients experience increasing muscular degeneration and atrophy as a result. Over time, chronic inflammation plays a role in the development of this damage. For individuals with Duchenne muscular dystrophy (DMD) who are two years of age or older, the dissociative steroid agamree (vamorolone) is used to maintain muscle function and reduce inflammation. Santhera Pharmaceuticals sold the rights to market Agamree in North America to Catalyst Pharmaceuticals. The treatment was first created by ReveraGen BioPharma. Current clinical management guidelines state that mechanical ventilatory assistance is typically started at night to address hypoventilation and sleep-related breathing issues sometime in the second to third decade of a patient's life. All patients eventually require help breathing, even throughout the day, to survive as their respiratory muscles continue to degenerate. Because of the disease's morbidity and mortality, DMD is linked to a significant burden on afflicted individuals, unpaid caregivers, and society at large. Mainly, the DMD is caused by a genetic mutation in the DMD gene causes dystrophin, a protein necessary for muscle function, to be absent, leading to progressive muscle weakness and degeneration. This is the cause of Duchenne muscular dystrophy (DMD). The symptoms include in DMD include Muscle weakness, regular falls, walking on tiptoe, difficulty standing up, delayed onset of sitting, etc. Vamorolone is a corticosteroid class drug, and the formulation present in the market is named Agamree. And the administration form of this formulation is oral suspension.

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 12
Issue: 1
PageNo: 3442-3458

TO TREAT DUCHENNE MUSCULAR DYSTROPHY WITH AGAMREE (VAMOROLONE)

Available:https://ijirt.org/article?manuscript=180932

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now